$QURE earnings report

uniQure reported third-quarter 2026 revenue of $5.2 million and a net loss of $61.2 million while the FDA granted Priority Review to the AMT-130 BLA, with a PDUFA target action date of May 1, 2027. AlphAI read uniQure's Third quarter of 2026 filing as mixed. 2 quarters are on record below.

Third quarter of 2026

AlphAI · Earnings readQURE · Third quarter of 2026 · ended September 30, 2026

uniQure reported third-quarter 2026 revenue of $5.2 million and a net loss of $61.2 million while the FDA granted Priority Review to the AMT-130 BLA, with a PDUFA target action date of May 1, 2027.

→Mixed quarter

Revenue increased to $5.2 million and net loss narrowed to $61.2 million, while cash, cash equivalents and investment securities rose to $768.4 million and are expected to fund projected operating expenses into 2030. The operating update is centered on Priority Review for AMT-130, but operating expenses increased and the BLA remains subject to FDA review and a planned confirmatory study.

Revenue
$5.2M
increase of $1.5 million y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, three months ended September 30, 2026GAAP$5.2M–increase of $1.5 million
Cost of license revenues, three months ended September 30, 2026GAAP−$236K––
Research and development expenses, three months ended September 30, 2026GAAP$35.5M–$1.1 million increase
Selling, general and administrative expenses, three months ended September 30, 2026GAAP$23.9M–$4.5 million increase
Total operating expenses, three months ended September 30, 2026GAAP−$59.67M––
Other income, three months ended September 30, 2026GAAP$1.69M––
Other expense, three months ended September 30, 2026GAAP−$195K––
Loss from operations, three months ended September 30, 2026GAAP−$52.98M––
Non-operating items, net, three months ended September 30, 2026GAAPexpense of $7.6 million–$13.3 million decrease in net non-operating expense
Loss before income tax expense, three months ended September 30, 2026GAAP−$60.54M––
Income tax expense, three months ended September 30, 2026GAAP−$676K––
Net loss, three months ended September 30, 2026GAAP$61.2M––
Basic and diluted net loss per ordinary share, three months ended September 30, 2026GAAP$0.88 basic and diluted loss per ordinary share––
Weighted average shares used in computing basic and diluted net loss per ordinary share, three months ended September 30, 2026GAAP69,900,863––
Cash, cash equivalents and investment securities, September 30, 2026GAAP$768.4M––
Long-term debt, September 30, 2026GAAP$50.34M––
Liability from royalty financing agreement, September 30, 2026GAAP$497.3M––
Total assets, September 30, 2026GAAP$940.6M––
Total liabilities, September 30, 2026GAAP$645.9M––
Total shareholders' equity, September 30, 2026GAAP$294.7M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Projected operating expenses into 2030 outlook

  • NoteThe Company expects that these resources will be sufficient to fund projected operating expenses into 2030.
  • NotePDUFA target action date of May 1, 2027.
  • NoteThe Company plans to initiate patient screening, beginning in the U.S., by the end of 2026.
  • NoteThe Company expects to present updated results in the first half of 2027.

What drove it

  • Revenue increased by $1.5 million due to an increase in license revenue compared to the prior period.
  • Research and development expense increased primarily from a $3.6 million increase in employee and contractor-related expenses including share-based compensation, partially offset by a $2.3 million decrease in direct research and development expenses.
  • The decrease in direct research and development expenses reflected a $4.1 million reduction in process validation expenses related to ifezuntirgene inilparvovec, partly offset by a $1.5 million increase in expenses related to AMT-260 and a $1.7 million increase in expenses related to preclinical activities and technology innovation projects.
  • Selling, general and administrative expense increased primarily from a $3.0 million increase in employee and contractor-related expenses, including share-based compensation, a $0.7 million increase in professional fees and a $0.7 million increase in information technology costs to support potential commercial launches of ifezuntirgene inilparvovec.
  • The decrease in net non-operating expense was primarily due to a $6.3 million reduction of expenses related to pre-funded warrants and a $6.8 million improvement of net interest income.
  • The FDA accepted the AMT-130 BLA under the Accelerated Approval pathway and granted Priority Review, with a PDUFA target action date of May 1, 2027.

Concerns

  • The BLA is supported by 36-month data from 12 high-dose patients compared with a propensity score-matched external control.
  • At 48 months, cUHDRS showed a 44% slowing of disease progression versus the updated external control, with non-significant p=0.144.
  • AMT-191 dosing had previously been paused after asymptomatic liver enzyme elevations in two mid-dose patients, which resolved following a course of immunosuppression.
  • The FDA may ultimately conclude that the Phase I/II trial data for ifezuntirgene inilparvovec are not sufficient to support approval, according to the company's forward-looking statements.

What to watch

  • FDA action on the AMT-130 BLA by the PDUFA target action date of May 1, 2027.
  • Initiation of U.S. patient screening for the AMT-130 confirmatory study by the end of 2026.
  • The approximately 200-patient AMT-130 confirmatory study, randomized in a 2:1 ratio to treatment or standard of care, with TFC as the primary endpoint at 36 months.
  • Updated Phase I/IIa results for AMT-260 and updated Phase I/II results across all AMT-191 dosing cohorts, both expected in the first half of 2027.
  • Progress in building field medical, market access and strategic account teams ahead of a potential AMT-130 launch.

Balance sheet and cash flow

  • Cash and cash equivalents: $ 98,442 as of September 30, 2026, compared to $ 80,240 as of December 31, 2025.
  • Current investment securities: $ 570,021 as of September 30, 2026, compared to $ 542,301 as of December 31, 2025.
  • Non-current investment securities: $ 99,967 as of September 30, 2026, compared to - as of December 31, 2025.
  • Other investments: $ 31,539 as of September 30, 2026, compared to $ 30,237 as of December 31, 2025.
  • Total current assets: $ 692,545 as of September 30, 2026, compared to $ 655,986 as of December 31, 2025.
  • Total non-current assets: $ 248,006 as of September 30, 2026, compared to $ 168,922 as of December 31, 2025.
  • Accounts payable: $ 6,173 as of September 30, 2026, compared to $ 5,170 as of December 31, 2025.
  • Accrued expenses and other current liabilities: $ 50,979 as of September 30, 2026, compared to $ 41,292 as of December 31, 2025.
  • Liability related to pre-funded warrants: - as of September 30, 2026, compared to $ 12,595 as of December 31, 2025.
  • Total current liabilities: $ 60,142 as of September 30, 2026, compared to $ 62,919 as of December 31, 2025.
  • Total non-current liabilities: $ 585,756 as of September 30, 2026, compared to $ 563,088 as of December 31, 2025.
  • No operating cash flow or free cash flow was reported.

Analysis

Third-quarter revenue was $5.2 million, compared with $3.7 million in the same period in 2025. The company attributed the $1.5 million increase to higher license revenue. The business remained loss-making, with a $61.2 million net loss and $0.88 basic and diluted loss per ordinary share, compared with a $80.5 million net loss and $1.38 basic and diluted loss per ordinary share in the comparative period.

Operating expense increased year over year. Research and development expense was $35.5 million versus $34.4 million, as higher employee and contractor-related costs including share-based compensation were partly offset by lower direct research and development expense. Selling, general and administrative expense was $23.9 million versus $19.4 million, driven by recruitment, professional fees and information technology costs supporting potential commercial launches. Non-operating expense improved by $13.3 million, principally from lower pre-funded-warrant expense and improved net interest income.

The primary operating catalyst is AMT-130 in Huntington’s disease. The FDA accepted the BLA submitted under the Accelerated Approval pathway, granted Priority Review, and set a May 1, 2027 PDUFA target action date. The company also aligned with the FDA on a confirmatory study designed as a randomized, standard-of-care-controlled trial enrolling approximately 200 patients, with TFC as the primary endpoint at 36 months. U.S. patient screening is planned by the end of 2026.

Clinical evidence cited for AMT-130 includes 36-month data from 12 high-dose patients supporting the BLA and updated analyses from the Phase I/II program. The 48-month cUHDRS result in 12 high-dose patients showed a 44% slowing versus the updated external control with non-significant p=0.144, while TFC showed a 61% slowing with nominal p=0.008. The company reported $768.4 million of cash, cash equivalents and investment securities as of September 30, 2026 and expects these resources to fund projected operating expenses into 2030. The filing reported no operating cash flow, free cash flow, repurchases or dividends.

Management, verbatim

Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease.

Matthew Kapusta, chief executive officer at uniQure

We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.

Matthew Kapusta, chief executive officer at uniQure

As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans.

Matthew Kapusta, chief executive officer at uniQure

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Segment revenue was not reported.
  • Non-GAAP revenue, earnings, operating income, net income, EPS or other non-GAAP financial measures were not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • Prior-quarter comparisons were not reported.
  • A revenue, gross margin, operating expense or tax-rate guidance range was not reported.
  • CFO commentary was not provided.
  • The previous outlook covered funding into 2030 and regulatory and clinical milestones only, with no numeric guidance for the third quarter of 2026 results, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter of 2026

AlphAI · Earnings readQURE · second quarter of 2026 · ended June 30, 2026

uniQure reported a $81.1 million net loss for the second quarter of 2026, raised $259 million in a follow-on offering, and maintained plans for U.S. and U.K. AMT-130 regulatory submissions in the third quarter of 2026.

→Mixed quarter

Revenue increased and the company materially extended its stated cash runway through the $259 million offering, while AMT-130 regulatory progress remained on track. However, net loss widened to $81.1 million, driven in part by unfavorable foreign currency and pre-funded warrant valuation changes, and AMT-191 mid- and high-dose dosing remains paused following dose-limiting liver enzyme elevations.

Revenue
$5.8M
$0.5 million increase y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenueother$5.8M–$0.5 million increase
Research and development expensesother$34M–$1.4 million decrease
Selling, general and administrative expensesother$17.4M–$3.9 million increase
Other expenseother$8M––
Other non-operating items, netotheran expense of $27.0 million–$33.6 million increase in net non-operating expense
Net lossother$81.1M––
Basic and diluted loss per ordinary shareother$1.22 basic and diluted loss per ordinary share––
Cash, cash equivalents and current investment securitiesother$810.3M––

into 2030 outlook

  • NoteThe Company expects that these resources will be sufficient to fund projected operating expenses into 2030.
  • NoteThe Company expects to submit a BLA in the third quarter of 2026.
  • NoteThe regulatory submission is progressing as planned for the third quarter of 2026.
  • NoteThe Company expects to complete enrollment in the second dose cohort in the Phase I/IIa study in the third quarter of 2026.
  • NoteThe Company expects to present updated results from the Phase I/IIa study in the first half of 2027.

What drove it

  • Revenue increased due to an increase in license revenue compared to the prior period.
  • The decrease in research and development expenses was driven by a $3.2 million decrease in other research and development expenses, partially offset by a $1.8 million increase in direct research and development expenses.
  • Direct research and development expense increased with higher spend on the AMT-260, AMT-162 and AMT-191 programs, partially offset by lower spend on AMT-130.
  • Selling, general and administrative expense increased primarily because of higher employee and contractor-related expenses, including share-based compensation, to support potential commercial launches of AMT-130.
  • Other expense increased primarily due to a $6.0 million increase in costs associated with the supply of HEMGENIX ® to CSL Behring.
  • Net non-operating expense increased primarily due to a $20.4 million unfavorable change in net foreign currency and a $16.0 million loss from changes in the fair value of the liability related to pre-funded warrants.

Concerns

  • The net loss was $81.1 million, compared to a $37.7 million net loss for the comparative period in 2025.
  • The FDA stated that the confirmatory study should be feasible within a reasonable timeline and be well underway, and potentially fully enrolled, at the time of accelerated approval.
  • Additional dosing in the AMT-191 mid- and high-dose cohorts remains paused pending further evaluation of asymptomatic liver enzyme elevations in two patients from the mid-dose cohort that were confirmed as dose-limiting toxicities.
  • The AMT-260 low-dose cohort showed variable changes in disabling seizures for three of six patients during months four through six of follow-up, ranging from a 33% decrease to a 36% increase compared to baseline.

What to watch

  • BLA submission for AMT-130 in the third quarter of 2026 and alignment with the FDA on confirmatory study design and analysis.
  • Presentation in September 2026 of AMT-130 data including four years of follow-up on 24 patients in the first two cohorts.
  • Progress of the U.K. regulatory submission for AMT-130 in the third quarter of 2026.
  • Completion of enrollment in the second AMT-260 dose cohort in the third quarter of 2026 and updated Phase I/IIa results expected in the first half of 2027.
  • Further evaluation of the AMT-191 liver enzyme elevations and the status of paused mid- and high-dose cohorts.

Balance sheet and cash flow

  • As of June 30, 2026, the Company held $810.3 million in cash, cash equivalents and current investment securities, compared to $622.5 million as of December 31, 2025.
  • In June 2026, the Company closed an upsized underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share.
  • The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were $259 million.

Analysis

Second-quarter revenue was $5.8 million, compared to $5.3 million in the same period in 2025. The company attributed the $0.5 million increase to higher license revenue. The filing did not report segment revenue, gross margin, operating income, or non-GAAP earnings measures, limiting visibility into the operating profitability profile beyond the reported expense lines and net loss.

Research and development expenses declined to $34.0 million from $35.4 million, as lower facility, employee and contractor-related, and contingent-consideration costs more than offset increased direct development spending. Direct research and development spending rose for AMT-260, AMT-162 and AMT-191, while AMT-130 spending was lower. Selling, general and administrative expenses rose to $17.4 million from $13.5 million, driven primarily by employee and contractor-related costs, including share-based compensation, associated with personnel recruited to support potential AMT-130 commercial launches.

The net loss widened to $81.1 million, or $1.22 basic and diluted loss per ordinary share, from $37.7 million, or $0.69 basic and diluted loss per ordinary share. Other expense increased to $8.0 million primarily due to higher HEMGENIX ® supply costs. Other non-operating items shifted to an expense of $27.0 million from a gain of $6.6 million, principally reflecting a $20.4 million unfavorable change in net foreign currency and a $16.0 million loss from changes in the fair value of the pre-funded warrant liability.

Capital resources strengthened during the quarter. The company closed an upsized offering of 5,686,813 ordinary shares at $45.50 per share for aggregate gross proceeds of $259 million. Cash, cash equivalents and current investment securities were $810.3 million as of June 30, 2026, compared with $622.5 million as of December 31, 2025. Management expects these resources to fund projected operating expenses into 2030, supporting the anticipated AMT-130 commercial launch and continued pipeline investment.

The principal operating catalyst is AMT-130. Following a June 2026 Type B meeting, FDA meeting minutes received in July confirmed alignment that an accelerated-approval BLA based on existing clinical data is reasonable, subject to further alignment on the confirmatory study. The company expects a U.S. BLA submission and a U.K. regulatory submission in the third quarter of 2026, followed by four-year AMT-130 data in September 2026. Pipeline execution remains active, but AMT-191 mid- and high-dose dosing remains paused after dose-limiting liver enzyme elevations in two mid-dose patients, while AMT-260 results showed early biological signals and a favorable safety profile in the first low-dose cohort.

Management, verbatim

Following a productive Type B meeting with the FDA, we remain on track to submit our BLA for AMT-130 in the third quarter — a milestone that reflects years of rigorous science, disciplined execution, and an unwavering commitment to the patients and families living with this devastating disease.

Matthew Kapusta, chief executive officer at uniQure

Not in the filing

stated, not guessed
  • Gross profit and gross margin
  • Operating income or loss
  • Total operating expenses
  • Income tax expense or benefit and tax rate
  • GAAP designation for reported financial measures
  • Non-GAAP revenue, earnings, EPS, or margin measures
  • Prior-quarter comparisons for reported metrics
  • Segment revenue and segment profitability
  • Operating cash flow
  • Free cash flow
  • Debt balance
  • Share repurchases
  • Dividend information
  • Quantified revenue guidance
  • Quantified gross-margin guidance
  • Quantified operating-expense guidance
  • Quantified tax-rate guidance

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about QURE earnings dates

When is uniQure's next earnings date?
AlphAI has no date for QURE yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.